Barings’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Barings’s Portfolio SCLN Stock Details SCLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-35,400	Closed	-$346K	–	1041
2017 Q1	$346K	Buy	35,400 +17,700	+100%	+$177K	﹤0.01%	977
2016 Q4	$191K	Hold	17,700	–	–	﹤0.01%	853
2016 Q3	$181K	Hold	17,700	–	–	﹤0.01%	773
2016 Q2	$231K	Hold	17,700	–	–	0.01%	839
2016 Q1	$195K	Hold	17,700	–	–	0.01%	897
2015 Q4	$163K	Hold	17,700	–	–	﹤0.01%	888
2015 Q3	$123K	Hold	17,700	–	–	﹤0.01%	872
2015 Q2	$174K	Hold	17,700	–	–	0.01%	931
2015 Q1	$157K	Hold	17,700	–	–	﹤0.01%	933
2014 Q4	$155K	Hold	17,700	–	–	﹤0.01%	910
2014 Q3	$122K	Hold	17,700	–	–	﹤0.01%	930
2014 Q2	$93K	Hold	17,700	–	–	﹤0.01%	955
2014 Q1	$81K	Hold	17,700	–	–	﹤0.01%	909
2013 Q4	$89K	Hold	17,700	–	–	﹤0.01%	905
2013 Q3	$90K	Hold	17,700	–	–	﹤0.01%	915
2013 Q2	$88K	Buy	+17,700	New	+$84.2K	﹤0.01%	868

Other funds holding SCLN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Barings's SCLN Position: Q2 2017 in Review

Barings sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2017, closing a stake of 35,400 shares — an estimated $346K sold.

Barings first reported a position in SCLN in Q2 2013 and held it in 16 quarters. The position peaked at $346K in Q1 2017. 142 funds tracked by Wall St. Rank hold SCLN as of Q2 2017.

Barings reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
Barings sold 35,400 Sciclone Pharmaceuticals Inc shares in Q2 2017, an estimated $346K.
Barings first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 16 quarters.
Barings's Sciclone Pharmaceuticals Inc position peaked at $346K in Q1 2017.
142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2017.

Based on Barings's 13F filing for Q2 2017, filed 14 Aug 2017.